AVR-48 / AyuVis - LARVOL DELTA

Novel Small Molecule Immunomodulator AVR-48 as an Adjuvant for Influenza Vaccine (PAS 2025) - No abstract available

Clinical • Immunomodulating • Infectious Disease • Influenza • Respiratory Diseases

Survival, Growth, Respiratory Mechanics, and Neurodevelopmental Outcome in Former Preterm Lambs Treated With AVR-48 to Prevent BPD (ATS 2024) - "Lambs breathed spontaneously while prone in a sling and were lightly sedated (Lorazepam). AVR-48 treatment significantly improved survival, and growth. The AVR-48 FPT and TR groups had better neurobehavioral outcomes than the vehicle FPT group. Respiratory mechanics and neurobehavior in FPT lambs, were improved to the levels comparable to TR lambs."

Late-breaking abstract • Neurodevelopmental • Prematurity • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases • TLR4

Anti-inflammatory and Immunomodulatory Activity of AVR-48 in Human Cord and Adult Blood Mononuclear Cells (PAS 2024) - "CBMCs treated with AVR-48+LPS show a decrease (~2-4-fold) in cytokine signals in IL-6, IL-8, TNF-α, IL-12, IL-1β, and IL-10, indicating anti-inflammatory efficacy as compared to LPS treated cells (Fig. 1A-F). CBMCs treated with AVR-48 alone while increased the phosphorylation of TIRAP and MyD88, indicating activation of TLR4 pathway, but decreased pNFkB."

Clinical • Immunomodulating • Bronchopulmonary Dysplasia • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Septic Shock • CXCL8 • IL10 • IL12A • IL1B • IL6 • MYD88 • TNFA

AVR-48 treatment improves respiratory system mechanics in former preterm lambs (WRMC 2024) - "During oscillometry, lambs breathed spontaneously while supported prone in a sling and lightly sedated (Lorazepam). AVR-48 appeared to improve overall body weight, survival, and indices of respiratory system mechanics in FPT lambs following methacholine challenge and equivalent to TC lambs. We suggest that AVR-48 is a promising molecule with potential therapeutic long-term benefit for preterm infants at risk of BPD."

Prematurity • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases • TLR4

Richard D. Rowe Award in Clinical Research: AVR-48 treatment improves lung function and structure in a preterm lamb model of bronchopulmonary dysplasia (PAS 2023) - No abstract available

Clinical • Prematurity • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases